The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isApproved in China in 2025 and in late-stage trials elsewhere.
- What to watchSevere upper belly pain that bores through to the back.
How Mazdutide works
Dual GLP-1/glucagon receptor agonist — incretin appetite control plus glucagon-driven energy expenditure and hepatic fat reduction.
Mazdutide is a GLP-1 and glucagon receptor dual agonist built on an oxyntomodulin backbone, and the ratio between its two arms is not published anywhere. Five registered-trial publications — a phase 1b, two phase 2s and two phase 3s Ji 2022 Zhang 2023 Ji 2023 Ji 2025 Gao 2026 — and not one prints a receptor potency ratio.
So derive it from the clinical data instead, which nobody does. The phase 2 in type 2 diabetes ran mazdutide against open-label dulaglutide in the same trial, which makes it the cleanest natural experiment in this cohort Zhang 2023. Over 20 weeks: HbA1c fell 1.41% to 1.67% on mazdutide and 1.35% on dulaglutide — essentially the same.
- Injectable
Research on Mazdutide5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Phase 3 human (China).
Human clinical evidence
Approved in China in 2025 and in late-stage trials elsewhere. A GLP-1/glucagon dual agonist licensed from Eli Lilly by Innovent, with phase 3 data in Chinese populations showing substantial weight loss.
The population matters when reading the numbers: the pivotal trials were run largely in Chinese participants at lower baseline BMI than Western obesity trials, so percentage results are not directly comparable to tirzepatide's.
Correlative data
Real-world use is essentially confined to China and very recent. Trial reports note the class-typical GI profile plus increased heart rate, which is the glucagon arm showing up.
How the mechanism reads
Based on oxyntomodulin, a naturally occurring gut hormone that intrinsically hits both GLP-1 and glucagon receptors — so this is a biomimetic design rather than an engineered chimera.
MechanisticSame dual logic as survodutide: GLP-1 suppresses intake, glucagon raises expenditure and mobilizes liver fat. Trials have also reported reductions in hepatic fat and uric acid consistent with the glucagon component.
Mechanistic
Sources
- Ji L, et al. EClinicalMedicine 2022 · PMID 36247927
- Zhang B, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care 2023 · PMID 37943529
- Ji L, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications 2023 · PMID 38092790
- Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine 2025 · PMID 40421736
- Gao L, et al. JAMA 2026 · PMID 42251595
- Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology 2024 · PMID 39002641
- Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
- Yang Y, et al. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Diabetes, Obesity and Metabolism 2023 · PMID 37860884
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
Mazdutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Personal or family history of medullary thyroid cancer or MEN2: GLP-1 receptor agonists carry that rodent C-cell signal.
- History of pancreatitis or gallstone disease: slowed gallbladder emptying and pancreatic stimulation are class effects.
- Type 1 diabetes or insulin or sulfonylurea use: lower appetite plus GLP-1 action raises hypoglycemia risk.
- Pregnancy or trying to conceive, and under 18.
- Resting heart rate already high or a rhythm disorder: the glucagon arm tends to lift heart rate.
What’s expected
- Smaller appetite and earlier fullness from GLP-1 action on the brainstem and slowed gastric emptying.
- Nausea and loose stools early, easing as the body adapts.
- Faster resting pulse, a known trait of glucagon receptor activation.
- Falling liver fat, because the glucagon arm drives hepatic fat burning.
Watch for
- Severe upper belly pain that bores through to the back.
- Right-sided pain with fever or yellow eyes.
- Neck lump, hoarseness or trouble swallowing.
- Vomiting that will not stop, with dizziness from dehydration.
Labs that tell you it’s working
- HbA1c (Hemoglobin A1c)
- Lipase
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
Dual GLP-1 and glucagon agonist: GLP-1 explains appetite, pancreas and gallbladder effects; glucagon explains pulse and liver fat. PMID 36247927 PMID 38092790
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Mazdutide FAQ4 common questions
- Is Mazdutide approved for human use?
- No. Mazdutide is a research compound.
- What is Mazdutide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Comprehensive Metabolic Panel; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Mazdutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




